drugset / Trial / NCT02227173

A Phase 1 Drug-drug Interaction Study in Healthy Volunteers

NCT02227173

Phase 1 Completed 20 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-label

Summary

This is an open-label, single-sequence, drug-drug interaction study in healthy male and female subjects. There is no formal research hypothesis to be statistically tested. It is expected that coadministration of BMS-986020 with montelukast, flurbiprofen, and digoxin may increase the exposure of montelukast, flurbiprofen, and digoxin.

Timeline

Start
2014-09
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986020 Small molecule Oral
Subject Digoxin Other / unclassified Oral
Subject Flurbiprofen Small molecule Oral
Subject Montelukast Other / unclassified Oral

Indications

No indication recorded.